anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Narrow resection margin hepatocellular carcinoma (NRM-HCC) has a high incidence of early recurrence. Our study was designed to identify prognostic factors in patients with NRM-HCC, establish and validate a nomogram model to predict early recurrence of NRM-HCC patients.
METHODS: We retrospectively analyzed data from 2957 NRM-HCC patients who underwent radical hepatectomy at three medical centers between December 2009 and January 2015. Patients were randomly assigned to a training cohort (n = 2069) and a validation cohort (n = 888). Using univariate and multivariate COX regression to determine early relapse factors in NRM-HCC patients, and used these factors to construct a nomogram. The accuracy of the prediction was evaluated using the C-index, receiver operating characteristic (ROC) and calibration curve. Decision curve analysis (DCA) assessed the predictive value of the models. Finally, the recurrence-free survival of different risks was analyzed using Kaplan-Meier (K-M) method.
RESULTS: The nomogram of NRM model contains alpha-fetoprotein (AFP), alkaline phosphatase (ALP), tumor size, tumor number, microvascular invasion (MVI), tumor capsular, and satellite nodules. The model shows good discrimination with C-indexes of 0.71 (95% CI: 0.69-0.72) and 0.72 (95% CI: 0.70-0.75) in the train cohort and test cohort respectively. Decision curve analysis demonstrated that the model is clinically useful and the calibration of our model was favorable. Our model stratified patients into two different risk groups, which exhibited significantly different early recurrence. The web-based tools are convenient for clinical practice.
CONCLUSIONS: NRM model demonstrated favorable performance in predicting early recurrence in NRM-HCC patients. This novel model will be helpful to guide postoperative follow-up and adjuvant therapy.
PURPOSE:To obtain an improver for renal disorder caused by warm blood arrest, containing, as an active ingredient, prostaglandin E1 or a lipid emulsion bearing its derivative and manifesting marked efficacy without side-effects with a reduced dose. CONSTITUTION:Soybean oil, phospholipid, prostaglandin E1 (abbreviated to PGE1) or its derivative and, when needed, additives such as emulsifying auxiliary or high-molecular-weight substances are mixed with heat and processed in a usual manner to prepare the subject lipid emulsion. In general, the emulsion preparation includes 100-0.2mug/ml of PGE1 or its derivative. The emulsion is administered by injection into veins or arteries and the dose is 0.1-10mug/kg body weight/day 1 or 2 portions. The lipid emulsion is not so deactivated in lungs and significantly improves the disorder in warm blood arrest, especially in implantation of kidney. The disorder caused by warm blood flow arrest is observed, when the blood flow is stopped to kidney.
Up to 200 adult and 250 pediatric (17 years of age or younger) subjects will be enrolled to obtain at least 200 evaluable subjects. At least four (4) subjects between the ages of 2 and 5 will be enrolled. Subjects will wear a total of two (2) sensors, one on the back of each upper arm.

Each subject will wear two sensors, from the same Sensor lot, one on the back of each upper arm. One or more unique sensor lots will be evaluated in this study. Subjects will make between four (4) and six (6) scheduled visits to the clinical study site, including the Enrollment/Screening Visit (Visit 1). Subjects aged 2 - 5 will have one (1) in-clinic visit where capillary blood testing will be performed. Based on the subjects age and/or weight, subjects age 6 or older, will have up to three in-clinic visits during which intravenous blood draws and YSI reference testing will occur. Based on the subjects' age, blood glucose levels may be manipulated.
A peripheral blood sample will be collected from HIV-infected women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed.
BACKGROUND: The experience of homelessness has been linked with developing poor health outcomes. Little is known about the risk of recurrent stroke among these individuals. This study investigated the correlates of developing recurrent stroke and subsequent mortality among Veterans with housing instability.
METHODS: Using a national sample of Veterans from the U.S. Department of Veterans Affairs who had an indicator of housing instability between 2014-2018 (n=659,987), we identified 15,566 Veterans who experienced incident stroke. We compared characteristics of Veterans who experienced incident stroke and did and did not experience recurrent stroke and conducted logistic regressions using a discrete-time survival framework to assess two outcomes: recurrent stroke and all-cause mortality.
RESULTS: Among our cohort, 91.3% did not experience recurrent stroke while 8.7% did during the observation period. The receipt of any level of primary care outpatient visits was associated with a reduction in the odds of recurrent stroke. Several medical diagnoses were also associated with increased odds of recurrent stroke, including hypertension (aOR 1.35, 95% CI 1.15-1.59), diabetes (aOR 1.21, 95% CI 1.07-1.36), and renal disease (aOR 1.17, 95% CI 1.02, 1.35). Veterans who used any level of VA Homeless Programs had reduced odds of all-cause mortality (high level: aOR 0.65, 95% CI 0.60-0.71; low level: aOR 0.66, 95% CI 0.60-0.73).
CONCLUSION: Our study found several predictors of developing recurrent stroke and subsequent death in a population of Veterans experiencing housing instability. Implications include the need to monitor closely high-risk patients who have experienced incident stroke and have other co-occurring needs.
After conventional periodontal treatment, photobiomodulation will be performed with a red laser (660 nm) using a DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW. As no gel will be applied, the application of the gel with an empty syringe will be simulated, and waited 5 minutes, to keep patients blind to the intervention received.
PURPOSE:To obtain a liposome useful as a drug carrier by dissolving a component material for liposome membrane and a polymer material having amphipathic property in an org. solvent, removing the solvent by distillation to obtain a solid, and swelling and dispersing this solid in a water-base solvent. CONSTITUTION:A liposome membrane material comprising phospholipid such as soybean, yolk, etc., and a polymer material having amphipathic property, such as hydroxypropylmethyl cellulose, etc., are dissolved in a volatile org. solvent such as diethyl ether, methylalcohol, etc. Then this solvent is removed by distillation to obtain a solid containing the liposome membrane component material. Then this solid is swolen and dispersed in a water-base solvent such as water, sodium chloride, etc., to obtain a liposome. The obtd. liposome is effective as a drug carrier and is industrially produced.
In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6+3 dose de-escalation design and will include a sentinel participant which will have a 3-day observation period prior to dosing of subsequent participants. Participants with one of the following three tumor types will be eligible for enrollment: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma).
A process of preparing a pharmaceutical solid comprises the steps of: (i) forming a mixture comprising an active pharmaceutical ingredient, a co-forming substance and one or more solvents; (ii) subjecting the mixture to cavitation under conditions of shear, elevated pressure and elevated temperature; and (iii) obtaining the pharmaceutical solid. Preferably, cavitation is performed at a pressure of 50 to 300MPa, and a temperature of 30 to 80ºC, and may be performed over a number of cycles. The one or more solvents may be an organic solvent, such as acetone and methanol. The active ingredient and the co-forming substance may be present in a stoichiometric ratio of 2:1 to 1:2. The pharmaceutical solid may be a co-crystal comprising the active ingredient and the co-forming substance. An example pharmaceutical solid comprises ketoconazole and oxalic acid. Preferably, the obtained crystals have a mean diameter of 10nm to 1µm. The pharmaceutical solid may comprise a polymeric stabiliser.
Lactate and ATP formation by aerobic glycolysis, the Warburg effect, is considered a hallmark of cancer. During angiogenesis in non-cancerous tissue, proliferating stalk endothelial cells (ECs) also produce lactate and ATP by aerobic glycolysis. In fact, all proliferating cells, both non-cancer and cancer cells, need lactate for the biosynthesis of building blocks for cell growth and tissue expansion. Moreover, both non-proliferating cancer stem cells in tumors and leader tip ECs during angiogenesis rely on glycolysis for pyruvate production, which is used for ATP synthesis in mitochondria through oxidative phosphorylation (OXPHOS). Therefore, aerobic glycolysis is not a specific hallmark of cancer but rather a hallmark of proliferating cells and limits its utility in cancer therapy. However, local treatment of angiogenic eye conditions with inhibitors of glycolysis may be a safe therapeutic option that warrants experimental investigation. Most types of cells in the eye such as photoreceptors and pericytes use OXPHOS for ATP production, whereas proliferating angiogenic stalk ECs rely on glycolysis for lactate and ATP production. (J Histochem Cytochem XX.XXX-XXX, XXXX).
The investigators have demonstrated that there exists a diurnal rhythm of natriuretic peptides (NPs) which tracks closely with the BP rhythm and is in an antiphase relationship with the rhythm of the RAAS (Renin-Angiotensin-Aldosterone System) hormones. The NP levels are lowest at night, and the renin and aldosterone levels are highest at nighttime. Furthermore, the investigators have demonstrated that obese individuals have a putative deficiency of NPs, and this is due to decreased production alongside increased clearance of NPs. LCZ696 is an FDA-approved inhibitor of neprilysin (an NP degrading enzyme) that augments the NP levels and also suppresses the RAAS. Hence, the confluence of putative NP deficiency among obese alongside the lower levels of NPs at nighttime and the increased activity of RAAS at night may contribute to the high-risk nocturnal non-dipping BP profile among obese individuals. Chronopharmacology (controlling the time of medication administration) to synchronize the NP-RAAS axis targeting anti-hypertensive medications with the inherent biological NP-RAAS-BP rhythm axis may help in controlling the high-risk nocturnal BP non-dipping in obese. Investigators hypothesize that nighttime administration of NP augmenting and/or RAAS inhibition therapy in obese hypertensive individuals will help to improve their nocturnal BP rhythm. The investigators aim to conduct a patient-oriented physiological clinical trial to assess the effect of timing of administration of NP-RAAS axis therapy on restoring the normal BP rhythm. This study is a 2x2 factorial design trial, wherein individuals will be randomized to either daytime dosing or nighttime dosing of either LCZ696 or valsartan. The investigators will study the effect of timing of NP augmenting and/or RAAS inhibiting therapy on the nighttime BP profile in obese hypertensive patients with nondipping nocturnal BP. The investigators will also assess the effect of NP augmentation in an NP deficient population on the nocturnal BP profile, i.e., in obese hypertensives with nondipping nocturnal BP. The investigators will also examine the impact of NP augmenting-RAAS inhibiting therapy on the NP levels and the physiological diurnal rhythms.

This study will assess the physiological implications of chronopharmacology of anti-hypertensive therapy and assess a potentially novel approach of using the inherent biological rhythms to reduce the normal BP rhythmicity in a high-risk population
<P>PROBLEM TO BE SOLVED: To provide bar soap producing massaging effects.  <P>SOLUTION: The bar soap S forms a bar shape, and has a prescribed polygonal shape of the cross-sectional contour shape in the direction to intersect the axis line x thereof at right angles in any position in the direction of the axis line x thereof. Each side 1 of the polygon is formed with a surface 2 helically continuous around the axis line, respectively. The length is within the range of 15-25 cm, and the diameter of an imaginary circle in which the polygon is inscribed is within the range of 30-45 mm. Furthermore, the prescribed polygonal shape includes a pentagon, hexagon, or heptagon.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE:To obtain an extract of a specific value of the total N content, by extracting crushed NATTO (fermented soybeans) with aqueous ethanol, precipitating the extract with a specific concentration of ethanol solution and dissolving again or dispersing the precipitate in more diluted ethanol solution. CONSTITUTION:Crushed NATTO is combined with an aqueous ethanol of about 20V/V%, gently stirred one overnight, then filtered. The filtrate is combined with anhydrous ethanol and left to stand day and night, as being gently stirred at 40 deg.C. The precipitate is separated, washed with 70V/V% ethanol solution several times to collect a viscous lump. The lump is dissolved or dispersed in 10V/V% ethanol solution so that the total N content becomes 0.03-10W/V% to give the subject NATTO extract. The extract can be processed into cosmetics, beverage and foods to improve the smoothness of skin and hair and touch after drying. The beverage therefrom dose not remind the drinkers that it originates from NATTO.
The goal of the present study was to assess the associations of dispositional mindfulness, diabetes distress, and glycemic outcomes for adolescents with type 1 diabetes as well as to use an iterative approach to developing a self-led scalable mindfulness-based intervention. A self-led mindfulness-based intervention may provide a mindfulness practice to help adolescents with type 1 diabetes improve glycemic outcomes through diabetes distress reduction while also being practical within a pediatric endocrinology clinic. A self-led intervention may also reduce the burden associated with mindfulness-based interventions. This is important considering the heightened emotional and time burden adolescents may already experience due to disease management and the intensity of a traditional mindfulness-based intervention.

This study had two primary aims. First, the investigators examined the associations between mindfulness and diabetes-related outcomes. It was hypothesized that at baseline, increased mindfulness would be associated with decreased diabetes distress and more optimal glycemic levels and that all three variables would share similar associations with related constructs including greater self-compassion, lower general stress, better psychosocial health, increased diabetes treatment engagement, and greater diabetes-related quality of life. The association between specific aspects of dispositional mindfulness and diabetes distress was also explored. Second, the investigators examined the acceptability, feasibility, and potential utility of self-led MBSR intervention. It was hypothesized that participation in a self-led MBSR intervention would be feasible and acceptable, evidenced by treatment attrition and participant feedback. It was also hypothesized that participants who received the self-led MBSR intervention would experience increased mindfulness and decreased diabetes distress compared to a waitlist control group.
An antimicrobial composition and methods of use are provided. The antimicrobial composition includes a water-soluble antimicrobial organosilane ammonium compound and a sugar. The composition may be in liquid, foam, ointment or gel form. The composition may include anti-inflammatory medications, alcohol and/or steroids. The antimicrobial composition may be used to treat eye infections in humans and animals. The antimicrobial composition may be applied directly to the surface of the eye. The antimicrobial composition may further be used to treat ocular related articles, including contact lenses, contact cases, instruments, pads and the like. The antimicrobial composition may be applied directly to the surface of the ocular related article during and/or after manufacture.
Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
The present study aimed to examine the association between the presence, number, and type of positive psychotic symptoms (PPS) and clinical severity in adolescent patients. Five hundred-six patients aged 11-17 years were assigned to either the noPPS (n = 341), the delusional beliefs only (del; n = 32), the hallucinations only (hall; n = 80), or the delusional beliefs and hallucinations (del&hall; n = 53) group. Generalized Structural Equation Modeling was applied to identify the best-fitting model representing clinical severity indicated by psychiatric diagnoses, depressivity, personality pathology, non-suicidal self-injury, suicide attempts, perceived stress, and psychosocial impairments, assessed by interviews and questionnaires. The groups were compared concerning the final model's factors. The final model consisted of three factors representing psychopathology and functional impairments, self-harming behavior, and perceived stress (BIC difference to reference model: 103.99). Participants with any PPS scored higher on all factors than the noPPS group (differences in SD: 0.49-1.48). Additionally, the del&hall group scored 1.31 SD higher on psychopathology and functional impairments than the hall group, and 1.16 SD higher on self-harming behavior compared to the del group. Finally, the hall group scored 0.84 SD higher on self-harming behavior than the del group, with no group differences in the other factors. In adolescent patients, the presence of PPS may represent a marker for a more severe form of mental disorder, with hallucinations being indicative of self-harming behavior. Early transdiagnostic assessment of PPS seems indicated as it may inform treatment in the context of clinical staging.
The ongoing COVID-19 pandemic has hit Northern Italy (including the Veneto region) particularly hard, causing several deaths and putting a huge strain on the Italian National Healthcare System. In the absence of specific treatments, preventing the infection from spreading remains the only effective measure. There is a lot of apprehension both from doctors (including dermatologists, rheumatologists and gastroenterologists) and their patients that immunosuppressive medications (biologics, methotrexate, ciclosporin and corticosteroids) might lead to an increased susceptibility to COVID-19 infection or negatively influence the course of the infection. However, there is currently a lack of scientific evidence to recommend whether immunosuppressive treatments should or should not be continued in patients who have no symptoms of COVID-19 infection. Besides, treatment discontinuation would cause flare-ups of diseases - such as plaque psoriasis, psoriatic arthritis and inflammatory bowel diseases - which are invalidating and have a relatively high prevalence in the Veneto population. In the Unit of Dermatology of the Azienda Ospedaliera Universitaria Intergrata di Verona alone, more than 2000 patients are currently being treated with immunosuppressive agents. As of now, there are no data available on the prevalence and incidence of COVID-19 infection in patients with immune-mediated diseases, nor can data from randomized clinical trials be extrapolated to the susceptibility to COVID-19 infection in patients on biologic drugs. This study aims to assess the prevalence and incidence of COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressive therapy and to identify associated risk factors. Such data would prove invaluable for clinicians dealing with patients on immunosuppressive agents during the coronavirus outbreak.
Common name: medicine for treating diarrhea. Component: the main component is gentamicin sulfate, which is a multi-component antibiotic and contains the following components: C1, C1a, C2a, C2, etc. Addible auxiliary agents are anhydrous sodium sulfite and sulfuric acid. Character: the product is colorless or nearly colorless transparent liquid. It has been proved by several research and tests that the medicine for treating diarrhea has a good curative effect on acute enteritis, chronic enteritis, bacterial dysentery, and the like after the medicine is orally taken. The drug components mentioned above can be taken as the main components and processed into oral medicines for curing acute enteritis, chronic enteritis, and bacterial dysentery.
Patients should be informed of the potential risks and benefits of FORTAMET® and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose, glycosylated hemoglobin, renal function, and hematologic parameters.

The risks of lactic acidosis, its symptoms, and conditions that predispose to its development, as noted in the WARNINGS and PRECAUTIONS sections, should be explained to patients. Patients should be advised to discontinue FORTAMET® immediately and to promptly notify their health practitioner if unexplained hyperventilation, myalgia, malaise, unusual somnolence, or other nonspecific symptoms occur. Once a patient is stabilized on any dose level of FORTAMET®, gastrointestinal symptoms, which are common during initiation of metformin therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.

Patients should be counseled against excessive alcohol intake, either acute or chronic, while receiving FORTAMET®.

FORTAMET® alone does not usually cause hypoglycemia, although it may occur when FORTAMET® is used in conjunction with oral sulfonylureas and insulin. When initiating combination therapy, the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members (see Patient Information Printed Below).

Patients should be informed that FORTAMET® must be swallowed whole and not chewed, cut, or crushed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft mass that may resemble the original tablet (see Patient Information).